Pfizer expands gene therapy with Bamboo acquisition

Pfizer has acquired Bamboo Therapeutics, a biotechnology company based in North Carolina.

The acquisition, which was made public on Monday, August 1, will expand Pfizer’s expertise in gene therapy by providing it with several clinical and pre-clinical assets that will add to the company’s rare disease portfolio.

Bamboo focuses on developing gene therapies for the potential treatment of patients with certain rare diseases related to neuromuscular conditions and those affecting the central nervous system.

Mikael Dolsten, president of Pfizer worldwide research and development, said: “The field of gene therapy research has made tremendous strides in recent years, and we are pleased to be able to further enhance our leadership position in this area through this transaction with Bamboo.”

Pfizer has been investing in gene therapy in recent years. It has also created a research group in London to identify potential gene therapy projects.